Holen Sie sich die Stockscreener-App
158.88
1.26%
-1.155
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$160.04
Offen:
$158.31
24-Stunden-Volumen:
337.98K
Relative Volume:
0.11
Marktkapitalisierung:
$246.65B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
47.72
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
-2.23%
1M Leistung:
-2.10%
6M Leistung:
-18.94%
1J Leistung:
+94.57%
1-Tages-Spanne:
$157.78
$159.05
1-Wochen-Bereich:
$157.78
$165.74
52-Wochen-Spanne:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
159.04 | 248.21B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,132.46 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.95 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.34 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.03 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
139.04 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca stock holds after RBC starts coverage at GBP145 - AD HOC NEWS
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - uk.finance.yahoo.com
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - AD HOC NEWS
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - kalkinemedia.com
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline - AD HOC NEWS
AstraZeneca reports tozorakimab COPD trial results - grafa.com
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment - Benzinga
AstraZeneca PLC : Buy rating from JP Morgan - marketscreener.com
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD - Pharmaceutical Technology
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - Bloomberg.com
AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study - London South East
AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study - marketscreener.com
AstraZeneca hails tozorakimab licence application approval in US - London South East
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
AstraZeneca (AZN) says Imfinzi combo extends survival in small cell lung cancer - Stock Titan
AstraZeneca (LSE:AZN) slumps today as combination chatter grips London pharma? - Kalkine Media
REGAstraZeneca PLCImfinzi+Imdelltra improved OS in small cell lung - TradingView
AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials - marketscreener.com
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? - Zacks Investment Research
AstraZeneca's Tozorakimab Shows Statistically Significant Efficacy in Late-stage Trials - marketscreener.com
AstraZeneca moves forward in COPD - marketscreener.com
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - CNBC
AstraZeneca sees positive result in lung disease drug trial - Breakingthenews.net
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - CNBC
New AstraZeneca (AZN) breast cancer treatment gets accelerated FDA nod—but only for some patients - Stock Titan
AstraZeneca PLC : Receives a Sell rating from Deutsche Bank - marketscreener.com
AstraZeneca PLC : Barclays maintains a Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 0.3 percent gain - AD HOC NEWS
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
AstraZeneca stock gains on FDA breast cancer approval and analyst support - AD HOC NEWS
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - The Globe and Mail
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval - proactiveinvestors.com
AstraZeneca stock gains on analyst support and July results - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Back in Focus After Fresh Regulatory News? - Kalkine Media
AstraZeneca PLC (AZN) Stock Analysis: Unpacking a 30% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer - Pharmaceutical Technology
AstraZeneca's breast cancer drug granted accelerated approval in the US - Sharecast.com
AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):